LPCN
Lipocine Inc.
NASDAQ · USHealthcareBiotechnology
$2.15-3.59%
Price as of Jul 20, 2026
LPCN financials
Lipocine Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.0M | $11.2M | -$2.9M | $500.0K |
| Cost of revenue | $8.6M | $0.00 | $10.2M | $8.6M |
| Gross profit | -$6.6M | $11.2M | -$13.0M | -$8.1M |
| Operating expenses | $3.8M | $12.4M | $4.9M | $4.1M |
| Operating income | -$10.4M | -$1.2M | -$17.9M | -$12.1M |
| Net income | -$9.6M | $8.4K | -$16.4M | -$10.8M |
| EBITDA | -$9.6M | $50.1K | -$16.3M | -$10.7M |
| Basic EPS | $-1.77 | $0.00 | $-3.14 | $-2.15 |
| Diluted EPS | $-1.69 | $-0.00 | $-3.14 | $-2.05 |
| Balance sheet | ||||
| Cash & equivalents | $5.2M | $6.2M | $4.8M | $3.1M |
| Total assets | $17.0M | $22.5M | $23.0M | $37.5M |
| Total liabilities | $2.5M | $1.5M | $2.6M | $1.9M |
| Stockholders’ equity | $14.5M | $21.0M | $20.4M | $35.6M |
| Total debt | $449.6K | $0.00 | $0.00 | $0.00 |
| Net debt | -$4.8M | -$6.2M | -$4.8M | -$3.1M |
| Cash flow | ||||
| Operating cash flow | -$9.8M | -$1.2M | -$11.9M | -$12.0M |
| Capital expenditure | $1.00 | -$90.1K | -$13.2K | -$133.8K |
| Free cash flow | -$9.8M | -$1.3M | -$11.9M | -$12.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | -$21.7K |